Table 1 GWAS summary-level data used in this study
Study | Author/Consortium | Year | Samples (N) | Population | PMID |
|---|---|---|---|---|---|
Phytosterols levels | |||||
Brassicasterol | Scholz et al. | 2022 | 8,790 | European | 35,013,273 |
Campesterol | Scholz et al. | 2022 | 9,758 | European | 35,013,273 |
Sitosterol | Scholz et al. | 2022 | 9,755 | European | 35,013,273 |
Stigmasterol | Scholz et al. | 2022 | 8,663 | European | 35,013,273 |
Neurodegenerative diseases | |||||
Alzheimer’s disease (IGAP) | Kunkle et al. | 2019 | 63,926 | European | 30,820,047 |
Alzheimer’s disease (IGAP + UKB) | Schwartzentruber et al. | 2021 | 472,868 | European | 33,589,840 |
Parkinson’s disease (IPDGC) | Nalls et al. | 2019 | 482,730 | European | 31,701,892 |
Parkinson’s disease age at oneset (IPDGC) | Blauwendraat et al. | 2019 | 28,568 | European | 30,957,308 |
Blood Lipids (GLGC)a | |||||
HDL cholesterol | Graham et al. | 2023 | 1,320,016 | European | 37,237,109 |
Non-HDL cholesterol | Graham et al. | 2023 | 1,320,016 | European | 37,237,109 |
Triglyceride | Graham et al. | 2023 | 1,320,016 | European | 37,237,109 |